Are MS Patients Making their Own Treatment Choices?


Physicians and patients offer differing accounts of how their treatment plans are chosen, a Dutch study found.

Patients with multiple sclerosis (MS) and neurologists have different experiences and outlooks when it comes to providing information and adhering to disease modifying drugs (DMDs), according to recent research published in Patient Preference and Adherence.

The study, conducted by Leo H Visser, MD, of the Department of Neurology, Elisabeth-TweeSteden Hospital in Tilburg, Netherlands and colleagues, was published on April 26, 2016.

The researchers wanted to find out how the perspectives of MS patients and neurologists regarding injectable DMDs differed concerning both the choice of treatment and the course of that treatment. In order to carry out their investigation, they asked MS patients and neurologists specializing in MS to completed “semi structured Internet-based questionnaires” according to the authors. The neurologists who participated were not necessarily treating the patients who participated.

“Data were collected between July 2014 and June 2015,” said the researchers. There were 49 questions on the patient questionnaire and it took about 20 minutes to complete. The neurologists completed a 34-question survey, which took about 15 minutes. A total of 107 patients and 18 neurologists completed the respective questionnaires.

When it came to whether or not patients should be responsible for choosing a treatment following discussions with a physician, 83% of the neurologists and 59% of the patients agreed that the selection should be in the hands of the patients. Only 27% of the patients said “treatment options were discussed and a treatment recommended by their physician,” while 72% of the neurologists “stated that their patients were fully involved in the decision process,” according to the researchers.

The two groups also differed when it came to treatment goals, as well as whether or not those goals are being adequately discussed. Most neurologists, 94%, said that patients take a break or stop taking the treatment due to side effects; however, most patients (74%) said they stopped treatment or took a break because of “physical factors.” A full 80% of the patients reported side effects from DMDs and 50% of them said the side effects affected their day-to-day lives.

The researchers conclude, “This information on patient and neurologist perspectives may be very helpful for health care professionals and professionals in health care education.” They go on to say that educational programs for both patients and neurologists could improve communication and patient involvement, and that accurate and accessible sources of information, such as websites, brochures, expert summaries of relevant studies could also be helpful for both patients and physicians.

Related Videos
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
John Harsh, PhD
© 2024 MJH Life Sciences

All rights reserved.